Pangea Wellness Inc.
CSE: PNGA | OTCQB: PNGAF
Leading North America with innovative, clean-label wellness products blending tradition and innovation.
Disseminated on behalf of Pangea Wellness Inc.
Pangea Wellness Inc. (CSE: PNGA) is a Vancouver-based natural supplement company that operates from a CFIA- and FDA-certified facility in Surrey, British Columbia. As the parent company of Amino Innovations, the Pangea team delivers science-backed, non-invasive, highly effective solutions that naturally align with biology. No gimmicks. No shortcuts. Just real results.
Pangea's Market Position
Pangea’s subsidiary Amino Innovations, delivers next-gen peptides designed to supercharge mood, boost brainpower, spark hair growth, smooth skin, strengthen immunity, and support longevity—all without needles or prescriptions.
Company leaders are dedicated to advancing health and wellness by providing consumers with innovative peptide therapies through effective and accessible delivery systems, with product lines including peptide formulations for stress management, gut health, longevity, hair health, skin repair and sleep health. Through Pangea, Amino Innovations intends to develop delivery systems that position it to be the world’s first needleless peptide company.
Why Investors Should Consider Pangea and Amino Innovation Products
- Competitive Advantage – alternative peptide treatments require prescriptions, are very costly and impact patient time going for treatments and patient preference for non-invasive delivery creates enormous untapped market opportunity.
- Peptide Therapeutics Market – Double-Digit Growth. The global peptide therapeutics market size was estimated at $117.26 billion in 2024 and is projected to reach $260.25 billion by 2030, growing at a CAGR of 10.77%.
- Oral Protein and Peptide Market – The global oral proteins and peptides market, valued at $8.07 billion in 2024, stood at $9.31 billion in 2025 and is projected to advance at a resilient CAGR of 16.4% from 2025 to 2030, culminating in a forecasted valuation of $19.93 billion.
- Comprehensive Product Portfolio Addressing High-Value Health Segments – Pangea’s Amino Innovations sells products that help people with: Recovery & Performance, Longevity & Anti-Aging, Cognitive Enhancement, Gut Health, Skin and Hair Health and Stress Management – all cater to the modern healthy lifestyle.
- Needle-Free Innovative Peptide Therapy – and revolutionary market position to become world’s first needleless peptide company.
Industry Outlook: Peptide Therapeutics & Oral Delivery Markets 2025 and Beyond
Peptide Therapeutics – Unprecedented Growth Trajectory
The peptide therapeutics market represents one of the fastest-growing segments in healthcare:
Market Size Projections:
- Global peptide therapeutics market projected to reach $260.25 billion by 2030, growing at 10.77% CAGR.
Source: Peptide Therapeutics Market Size | Industry Report, 2030 - Market estimated to grow from $72.2 billion in 2024 to $84.2 billion in 2025 and $162.4 billion by 2035, at 6.8% CAGR
Source: Global Peptide Therapeutics Market Size & Trends Report - The peptide therapeutics market is projected to grow at a CAGR of 9.5% from 2025 to 2035, reaching over $123.2 billion by 2035
Source: Peptide Therapeutics Market – Growth and Forecast to 2035 - Global peptide therapeutics market size estimated at $49.13 billion in 2024 and predicted to increase to approximately $83.75 billion by 2034, expanding at a CAGR of 5.31%
Source: Peptide Therapeutics Market Size and Forecast 2025 to 2034
Peptide's Explain
A Bright Future Ahead...
"The convergence of breakthrough delivery technology, massive unmet customer need, substantial market growth, and pharmaceutical industry validation creates a potentially once-in-a-generation opportunity for Pangea with Amino Innovations products.
Amino Innovations is positioned to become the category leader in needleless peptide therapy—a market transforming shift. With our $2.4 million acquisition valuation entering markets collectively worth over $260 billion and growing at double-digit CAGRs, we believe Amino Innovations offers exceptional risk-reward asymmetry for people that may consider the potential in biotechnology innovation, consumer wellness, and pharmaceutical-grade health optimization."
— Pratap Sandhu, CEO
Investor Resources
Recent News
- Amino Innovations Appoints Dave Asprey, Jim Gunning, and Travis Rosbach as Strategic Advisors to Support Brand Growth and Market Expansion – December 5, 2025
- Amino Innovations Launches Wholesale Program to Bring Human Peptide Science to Clinics, Retailers., and Wellness Centers Nationwide – December 2, 2025
- Pangea Announces Filing of Amended and Restated Interim Financial Statements and Management’s Discussion and Analysis – November 14, 2025
- Pangea Announces Name Change – November 14, 2025
- Amino Innovations Forms Strategic Research Partnership with University of Alberta Scientists to Advance Peptide Innovation – October 23, 2025
- Amino Innovations Develops Next-Generation Peptide Patch Platform to Redefine Everyday Wellness – October 21, 2025
- Pangea Engages Emerging Markets Consulting, LLC – October 15, 2025
- Amino Innovations Showcases Peptide Solutions at TheFitExpo Anaheim 2025, Generating Strong Consumer Engagement and Brand Momentum – August 13, 2025
- Pangea Natural Foods Inc. Closes Non-Brokered Special Warrant and Unit Private Placement – May 23, 2025
- Pangea Natural Foods Provides Corporate Update and Highlights Launch of Amino Innovations Products Line – April 9, 2025
Must Read OTC Markets/SEC policy on stock promotion and investor protection
Disclaimer
EMC has been paid $150,000 by Pangea Wellness Inc. | Please read our full disclaimer
Disclaimer
Emerging Markets Consulting, LLC (“We” or “Us”) are not securities dealers or brokers, investment advisers or financial advisers, and you should not rely on the information herein as investment advice. Pangea. made a one-time payment of US $150,000 to provide marketing services for a term of six months. This landing page is informational only and is solely for use by prospective investors in determining whether to seek additional information. This does not constitute an offer to sell or a solicitation of an offer to buy any securities. Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for your further investigation; they are not stock recommendations or constitute an offer or sale of the referenced securities. The securities issued by the companies we profile should be considered high risk; if you do invest despite these warnings, you may lose your entire investment. Please do your own research before investing ,including reading the companies’ SEDAR+ and SEC filings, press releases, and risk disclosures. It is our policy that information contained in this profile was provided by the company, extracted from SEDAR+ and SEC filings, company websites, and other publicly available sources. We believe the sources and information are accurate and reliable but we cannot guarantee it.
Forward Looking Statements
This landing page contains forward-looking statements about Pangea, which are identified by terms such as “anticipate,” “expect,” and “project.” These statements reflect current views regarding company performance, business goals, nutraceutical market expectations, and peptide market growth projections. The statements are based on current business and market expectations. However, they involve various risks and uncertainties, including potential delays, financial difficulties, operational challenges, and problems protecting intellectual property. Additional risks include possible regulatory approval delays, market disruptions, personnel issues, and competitive pressures. Given these risks and uncertainties, actual results may differ significantly from what is described in the forward-looking statements. Readers should not place undue reliance on these statements, which are only valid as of the article’s publication date and we undertake no obligation to update.